J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Joaquin Duato, CEO of J&J, stated: “Our increased US investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add US-based jobs but manufacture cutting-edge medicines to treat patients in America and around the world.”

The announced additional investments kicked off with the groundbreaking of a new biologics manufacturing facility in Wilson, North Carolina. This facility will expand J&J's capacity to manufacture next-generation medicines for people living with cancer, immune-mediated, and neurological diseases and is expected to create over 500 new positions at the site.

In addition to the new site in Wilson, the J&J’s plans include three new manufacturing facilities and the expansion of several existing sites across the company’s Innovative Medicine and MedTech businesses, as well as “significant” investments in R&D infrastructure and technology.

© Johnson & Johnson
© Johnson & Johnson

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.